Results 1 to 10 of about 373,288 (339)

Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism [PDF]

Endocrine Connections, 2022
Hypothyroidism is often associated with elevated serum levels of total cholesterol, LDL-C and triglycerides. Thyroid hormone (TH) affects the production, clearance and transformation of cholesterol, but current research shows that thyroid-stimulating ...
Huixing Liu, Daoquan Peng
semanticscholar   +3 more sources

Atherogenic dyslipidemia

Indian Journal of Endocrinology and Metabolism, 2013
Atherogenic dyslipidemia (AD) refers to elevated levels of triglycerides (TG) and small-dense low-density lipoprotein and low levels of high-density lipoprotein cholesterol (HDL-C).
C N Manjunath, Jayesh R Rawal, Paurus Mehelli Irani, K Madhu   +3 more
doaj   +3 more sources

Gut microbiota is a potential goalkeeper of dyslipidemia

Frontiers in Endocrinology, 2022
Dyslipidemia, as a common metabolic disease, could cause atherosclerosis, coronary heart disease, stroke and other cardio-cerebrovascular diseases.
Lirong Lei, Lirong Lei, Lirong Lei, Ning Zhao, Ning Zhao, Ning Zhao, Lei Zhang, Lei Zhang, Lei Zhang, Jiamei Chen, Jiamei Chen, Jiamei Chen, Xiaomin Liu, Xiaomin Liu, Xiaomin Liu, Shenghua Piao, Shenghua Piao, Shenghua Piao   +17 more
doaj   +2 more sources

Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human

Frontiers in Endocrinology, 2021
White adipose tissue (WAT) possesses the endocannabinoid system (ECS) machinery and produces the two major endocannabinoids (ECs), arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG).
Chloé Buch, Tania Muller, Julia Leemput, Patricia Passilly-Degrace, Pablo Ortega-Deballon, Jean-Paul Pais de Barros, Bruno Vergès, Bruno Vergès, Tony Jourdan, Laurent Demizieux, Pascal Degrace   +10 more
doaj   +1 more source

Dyslipidemia and Cardiovascular Disease: Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies

Journal of Clinical Medicine, 2023
Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and dyslipidemia is one of the major risk factors [...].
Zhiyong Du, Yanwen Qin
semanticscholar   +1 more source

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides

Cells, 2023
Dyslipidemia is associated with endothelial dysfunction. Endothelial dysfunction is the initial step for atherosclerosis, resulting in cardiovascular complications.
Y. Higashi
semanticscholar   +1 more source

Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia

Microbiome, 2023
Background Diet-induced dyslipidemia is linked to the gut microbiota, but the causality of microbiota-host interaction affecting lipid metabolism remains controversial.
Hongtao Xu, Fang Fang, Kaizhang Wu, Jiangping Song, Yaqian Li, Xingyu Lu, Juncheng Liu, Liuyang Zhou, Wenqing Yu, Fei Yu, Jie Gao   +10 more
semanticscholar   +1 more source

Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime

Current Atherosclerosis Reports, 2023
Purpose of Review The goal of this article is to characterize the endothelium’s role in the development of hypertension and dyslipidemia and to point out promising therapeutic directions.
E. Dąbrowska, K. Narkiewicz
semanticscholar   +1 more source

Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy

Frontiers in Nephrology, 2023
ObjectiveThis study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model.MethodsDiabetes was induced in 8-week-old C57BL6/
Laetitia Jacquot, Océane Pointeau, Célia Roger-Villeboeuf, Patricia Passilly-Degrace, Rim Belkaid, Isaline Regazzoni, Julia Leemput, Chloé Buch, Laurent Demizieux, Bruno Vergès, Pascal Degrace, Glenn Crater, Tony Jourdan   +12 more
doaj   +1 more source

Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview

Diabetes & Metabolism Journal, 2023
Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes ...
Sang Heon Suh, Soo Wan Kim
semanticscholar   +1 more source